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Coronavirus disease (COVID-19) rapidly progresses to severe acute respiratory syndrome. This review aimed at
collating available data on COVID-19 infection in solid organ transplantation (SOT) patients.
We performed a systematic review of SOT patients infected with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The MEDLINE and PubMed databases were electronically searched and updated
until April 20, 2020. The MeSH terms used were ‘‘COVID-19’’ AND ‘‘Transplant.’’
Thirty-nine COVID-19 cases were reported among SOT patients. The median interval for developing SARS-CoV-2
infection was 4 years since transplantation, and the fatality rate was 25.64% (10/39). Sixteen cases were described in
liver transplant (LT) patients, and the median interval since transplantation was 5 years. The fatality rate among LT
patients was 37.5% (6/16), with death occurring more than 3 years after LT. The youngest patient who died was 59
years old; there were no deaths among children. Twenty-three cases were described in kidney transplant (KT)
patients. The median interval since transplantation was 4 years, and the fatality rate was 17.4% (4/23). The youngest
patient who died was 71 years old. Among all transplant patients, COVID-19 had the highest fatality rate in patients
older than 60 years : LT, 62.5% vs 12.5% (p=0.006); KT 44.44% vs 0 (p=0.039); and SOT, 52.94% vs 4.54% (p=0.001).
This study presents a novel description of COVID-19 in abdominal SOT recipients. Furthermore, we alert medical
professionals to the higher fatality risk in patients older than 60 years. (PROSPERO, registration number=
CRD42020181299)
KEYWORDS: Liver Transplantation; Systematic Review; COVID-19; Humans; Liver Diseases; SARS-CoV-2; 2019-
nCoV; Solid Organ Transplant Recipient.
’ INTRODUCTION
Coronavirus disease 2019 (COVID-19) is caused by the
novel coronavirus, severe acute respiratory syndrome corona-
virus-2 (SARS-CoV-2) (1,2). The first case of this disease was
reported in Wuhan, Hubei province, China, in December 2019
(3). Since March 2020, COVID-19 has spread worldwide and
has become a public health emergency and a pandemic of
international concern (4).
COVID-19 is extremely contagious and, in certain cases,
may rapidly progress to severe acute respiratory syndrome.
An unexpectedly high rate of SARS-CoV-2 infection has been
observed worldwide. An age gradient in the risk of death
was identified, and patients older than 60 years were repor-
ted to have a higher mortality rate (5,6), with a case fatality
rate close to 8–10% (5,6). Moreover, the presence of comor-
bidities results in increased mortality, with multiorgan
dysfunction (1,2).
Data on COVID-19 in solid organ transplant (SOT), liver
transplant (LT), and kidney transplant (KT) patients are
scarce (7). Mazzafero et al. (8) reported a novel experience
with several COVID-19 cases at an Italian transplant center
in Lombardy (8). Another case series from Italy showed that
children who had received LTs were not at a higher risk for
severe SARS-CoV-2 infection despite being immunosup-
pressed (9).
Transplant societies and guidelines were initially estab-
lished to decrease the risk of infection and protect health care
professionals. Recipients and donors may be at risk of being
carriers of SARS-CoV-2 or contracting active COVID-19
through contact with patients who have COVID-19 or through
exposure to SARS-CoV-2 (10).
Insufficient data on infected SOT recipients are available,
particularly data regarding the management of immunosup-
pressants and fatality rates. This review aimed to collate the
available data that address the management of COVID-19
infection in abdominal SOT patients.
’ METHODS
Study identification
A systematic review of the literature on COVID-19
and transplantation was carried out. The MEDLINE and
PubMed databases (www.ncbi.nlm.nih.gov/pubmed) wereDOI: 10.6061/clinics/2020/e1983
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electronically searched and updated until April 20, 2020. The
MeSH terms used were ‘‘COVID-19’’ (entire related MeSH
terms: 2019 novel coronavirus, SARS-CoV-2 infection, 2019-
nCoV infection) AND ‘‘transplant.’’ The electronic biblio-
graphic database included MEDLINE-PubMed, EMBASE,
Cochrane Library, and Web of Science.
The terms and MeSH terms for the PubMed database
search were developed with the PICO structure: patient,
intervention, comparison or control, and outcome (PICO).
The terms for each group were combined with the ‘‘OR’’
operator. The results of the search terms forming the ‘‘P’’
(Patients) group were combined with those of search terms
forming the ‘‘I’’ (Intervention) group, with ‘‘AND,’’ and for
exclusion terms, with ‘‘NOT.’’
Participants/population: Adults and children who were
abdominal organ recipients and were diagnosed as having
COVID-19. Intervention(s), exposure(s): Adults and children
who were abdominal SOT recipients and tested positive for
COVID-19 that progressed to severe acute respiratory
syndrome. Comparator(s)/control: The control group was
selected from the group of patients who were not exposed
to SARS-CoV-2. We evaluated other groups of LT and KT
patients and various epidemiologic groups such as those
matched for age, sex, and comorbidities. Context Main
outcome(s): Survival after SARS-CoV-2 infection and out-
comes related to medical management, as a potential therapy
to this infection in this population; establishing guidelines
and programs to better treat this population.
This systematic review was registered in the international
database of prospectively registered systematic reviews
(PROSPERO, registration number=CRD42020181299). The
review protocol can be accessed online via the PROSPERO
website (https://www.crd.york.ac.uk/prospero/). The Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) checklist was adhered to when preparing
this manuscript (11,12,13). The review methodology followed
the recommendations published by PRISMA (11,12,13).
Study selection
Inclusion and exclusion criteria. Selection criteria were
used within the research question of the PICO structure. All
studies evaluated were written in English.
Case reports, letters to the editor, clinical randomized
controlled trials, non-randomized controlled trials, reviews,
consensus articles, and protocol studies were included.
Studies on organs other than the liver and kidneys, those
on tissues transplants, those on a novel therapy for COVID-
19, those on the impact of COVID-19 on the transplant
system, those on vaccine research, those involving patients
on hemodialysis, those on the clinical manifestation of
COVID-19, epidemiologic studies, those on elective or non-
transplant surgical procedures, and those on immunosuppres-
sion protocols that were unrelated to abdominal SOT and
COVID-19 were excluded.
Study data extraction
Data extraction was carried out independently by two
researchers, using the text, tables, and figures of the original
published articles. The quality of the studies selected and
the selection methods were evaluated by two independent
researchers (LSN and LYZ). In the case of a disagreement, the
researchers held a consensus meeting to reach a final
decision.
Statistical analysis
Quantitative and qualitative variables were presented as
number and percentage, median and range, or mean and
standard deviation. The COVID-19 prevalence and fatality
rates of patients who were older than 60 years were
calculated and compared. A Mann-Whitney U test was used
to compare independent samples, and po0.05 was consid-
ered significant. All tests were performed using IBM SPSS 25
software, with a=0.05 and a 95% confidence interval.
The data were generated using Review Manager Version
5.3 software provided by the Cochrane Collaboration (Rev-




The literature search revealed 113 articles, of which 24
articles were selected and analyzed in this review. Figure 1
depicts the flow diagram of the systematic literature search,
according to the PRISMA statement, and the selection criteria
for the articles.
We did not find well-designed randomized control trials,
cohorts, or prospective or retrospective studies. Most articles
were case series, letters to the editor, and editorials.
Data extraction and synthesis were performed specifi-
cally using articles on SOT with COVID-19 infection, that is,
24 articles. There were 11 articles regarding Liver transplan-
tation (Table 1), 14 articles on Kidney transplantation
(Table 2), and one article on SOT as presented with liver
and KT.
Solid organ transplant patients
Twenty-four articles on SOT patients were selected. Thirty-
nine cases were related to SOT and COVID-19 infection. The
median interval since transplantation to COVID-19 infection
was 4 years (range, 0.01 – 30.10). The overall fatality rate in
solid organ transplant patients was 25.64% (10/39), and the
fatality rate was 52.94% in patients older than 60 years
(p=0.001; Table 3).
Liver transplant patients
From the 11 articles included in the analysis of LT patients
infected by SARS-CoV-2, seven were case reports/corre-
spondences (8,9,14-18), 3 were consensuses (19-21), and one
article was a case series on overall SOT (7). The LT group
included a total of 16 cases, with a median interval since
transplantation of 5.95 years (range, 0.01-26.5). These cases
involved transplants in pediatric and adult patients, with no
reported deaths in children. Tacrolimus administration was
discontinued in two cases, with satisfactory evolution of
these patients; however, therapy with methylprednisolone
was maintained (Table 1). The LTcase fatality rate was 37.5%
(6/16). Six patients evolved to death, more than 3 years after
LT, with the youngest being 59 years of age (Table 1 and
Table 3).
Kidney transplant patients
Fourteen articles were included in the analysis of KT
patients with COVID-19. Among these, six were case
reports/case series (22-27), five were correspondences
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(10,28-31), one was a guideline (32), one an editorial (33), and
one was a case series on SOT (7). Twenty-three KTcases were
described. The median interval since transplantation was 4
years (range, 0.25–30.1). The fatality rate among KT patients
was 17.4% (4/23), and the youngest patient who died was
71 years. Immunosuppressive therapy was reduced or
suspended in 13 cases, with good clinical evolution in eight
patients (Table 2 and 3).
’ DISCUSSION
The transplant society’s recommendations and guide-
lines during the COVID-19 pandemic, with insufficient evi-
dence, consider LT and KT as safe procedures. The transplant
team should discuss the real risks and benefits of the
procedure and of immunosuppression therapy. On the basis
of the scarce data on SARS-CoV-2 infection, it is suggested
that therapy for COVID-19 patients be individualized. This
review provided data on SOT and COVID-19 infection.
In their study, Mazzafero et al. (8) reported that three
patients with severe COVID-19 among 111 long-term LT
survivors (who had undergone transplantation more than
10 years ago) died. The post-transplant course had been
uneventful for all three patients, and their immunosuppres-
sive regimen had been tapered gradually, with very low
trough concentrations of calcineurin inhibitors (two patients
receiving ciclosporin and one receiving tacrolimus) (8).
D’Antiga et al. (9) reported a case series from a single
center in Italy, wherein children who received LTs were not at
increased risk for severe SARS-CoV-2 infection compared
with the general population despite being immunosup-
pressed (9). Nevertheless, this series was biased as it
involved the study of a population of children, which has a
lower incidence rate of SARS-CoV-2 infection.
The American Association for the Study of Liver Diseases
suggests that immunosuppression should not be reduced or
stopped in asymptomatic LT recipients (21). Immunosup-
pression, despite its immunomodulatory effect, did not seem
to increase the risk of severe COVID-19 disease in trans-
plantation patients. Given that a reactive innate immune
response might be responsible for the severe clinical
manifestations of SARS-CoV-2 infection, immunosuppres-
sion might be protective against COVID-19; however, this
needs further clarification.
Unrecognized COVID-19 infection among transplantation
recipients largely increases the potential of development of
severe immune suppression and postsurgical infection,
which may lead to multisystem organ damage or death.
A donor with unidentified COVID-19 infection may also
spread the virus to multiple recipients. The therapeutic
paradox is compelling in such patients: insufficient immu-
nosuppression results in graft loss due to rejection, whereas
excessive immunosuppression results in severe infection.
Strict screening protocols for organ transplant recipients and
donors, aimed at identifying carriers of SARS-CoV-2, must be
developed to aid in reducing further transmission (14).
However, the scarce data must be better analyzed with more
prolonged follow-up, and evaluations should be carried out
in recipients with COVID-19 infection.
Fernandez-Ruiz et al. (7) reported on 18 SOT recipients
with COVID-19. The majority of patients were KT recipients
(44.4% [8/18]), followed by LT (33.3% [6/18]) and heart
transplant recipients (22.2% [4/18]). The median patient age
was 71.0±12.8 years, with a predominance of male patients
(77.8% [14/18]), and the median interval since transplanta-
tion was 9.3 years. The case fatality rate was 27.8% (5/18).
Their study suggests that SARS-CoV-2 infection had a severe
course in SOT recipients (7). Moreover, this finding differs
from those of other publications, which report similar results
in non-transplanted patients with COVID-19 infection.
However, the current study, which analyzed overall SOT
cases, found that the median interval from transplantation to
COVID-19 infection was 4 years, and the case fatality rate
was 25.64% (10/39). Therefore, we demonstrated that SOT
populations have a higher mortality risk than that in non-
transplanted populations.
Figure 1 - Flow diagram of the systematic literature search according to the PRISMA statement. *Kidney transplant (KT) and liver
transplant (LT).
3
CLINICS 2020;75:e1983 COVID-19 in SOT patients


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































COVID-19 in SOT patients




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CLINICS 2020;75:e1983 COVID-19 in SOT patients
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































COVID-19 in SOT patients




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CLINICS 2020;75:e1983 COVID-19 in SOT patients







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































COVID-19 in SOT patients


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CLINICS 2020;75:e1983 COVID-19 in SOT patients
Nacif LS et al.
Moreover, Verity et al. (5) demonstrated an age gradient in
the risk of death in a COVID-19-infected population, which
showed that early estimates indicate the fatality ratio (5).
According to their findings, there was an increase in the
severity of COVID-19 with age in patients older than 60
years, along with a higher fatality rate (6). Moreover, in this
study, we observed a significant increase in fatality risk
among SOT patients older than 60 years.
The main limitations of this study were that only case
series and editorials on the topic were found in the literature.
To the best of our knowledge, the number of cases with
patients who had undergone SOT and were infected with
COVID-19 is considerably low. Further, only this review was
registered in the PROSPERO database (https://www.crd.
york.ac.uk/prospero/). However, there are several ongoing
clinical trials on COVID-19 (https://clinicaltrials.gov/ct2/
results?cond=COVID-19). Further data is warranted for more
definitive recommendations. The main contributions of this
systematic review are the novel description of COVID-19
infection in SOT recipients (LT and KT), especially in terms of
the management of the disease and immunosuppression
therapy, and the fact that it alerts medical professionals to the
higher fatality risk in SOT patients older than 60 years.
’ CONCLUSION
This study presents a novel description of COVID-19
infection in abdominal SOT recipients. Furthermore, we
alert medical professionals to the higher fatality risk in the
population of patients older than 60 years.
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